✦ LIBER ✦

Pergolide in Parkinson's disease: time for a change?

✍ Scribed by Katherine A Grosset; Donald G Grosset

Book ID: 117286390
Publisher: The Lancet
Year: 2004
Tongue: English
Weight: 57 KB
Volume: 363
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(04)16369-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pergolide therapy in parkinson's disease

✍ P. Jeanty; M. Kerchove; A. Lowenthal; H. Bruyne 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 543 KB

A total of 26 patients were treated with pergolide mesylate, a semi-synthetic ergot derivative with the property of direct dopamine activity. Of these patients, 18 suffered from late failure of L-dopa, while the remaining 8 had never before been treated with L-dopa. The aim of the trial was to study

PERGOLIDE AND LISURIDE FOR PARKINSON'S D

PERGOLIDE AND LISURIDE FOR PARKINSON'S DISEASE

✍ Lieberman, AbrahamN.; Leibowitz, Morton; Neophytides, Andreas; Kupersmith, Mark; 📂 Article 📅 1979 🏛 The Lancet 🌐 English ⚖ 318 KB

Pergolide effective in early Parkinson’s

Pergolide effective in early Parkinson’s disease

📂 Article 📅 1999 🏛 Adis International Limited (now part of Wolters Kl ⚖ 244 KB

Pergolide good value for money in Parkin

Pergolide good value for money in Parkinson's disease

✍ Hunter, Pamela 📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB

Pergolide-induced lung disease in patien

Pergolide-induced lung disease in patients with parkinson's disease

✍ J.A. KASTELIK; I. AZIZ; M.A. GREENSTONE; R. THOMPSON; A.H. MORICE 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Trial of subtherapeutic pergolide in de

Trial of subtherapeutic pergolide in de novo Parkinson's disease

✍ Katherine Grosset; Donald Grosset; Andrew Lees 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

## Abstract The effect of pergolide 25 μg twice daily on levodopa initiation was assessed in a randomized, placebo‐controlled, parallel group, double‐blind multicenter trial in 106 untreated early Parkinson's disease patients. The primary endpoint of mean time until levodopa was 520 days (95% confi